title: Deguelin suppresses the formation of carcinogen-induced aberrant crypt foci in the colon of CF-1 mice.
abstract: Deguelin [(7aS,BaS)-13,13a-dihydro-9,10-dimethoxy-3,3-dimethyl-3H-Bis[1]benzopyrano[3,4-b:6',5'-e]pyran-7(7aH)-one], a naturally occurring rotenone, has shown chemopreventive efficacy in several in vivo and in vitro models. In this report, the effectiveness of deguelin at inhibiting the development of AOM-induced colonic ACF was investigated in CF-1 mice. Loss of hex activity was assessed as a second biomarker. In an initial experiment, animals were given s.c. injections of AOM (10 mg/kg body weight) once a week for 2 weeks to induce ACF. Deguelin and vehicle (corn oil) were administered i.g. 7 days a week. Treatment was initiated 2 weeks prior to the first dose of carcinogen and continued for the duration of the study. The mean number of ACF for the control group was 29.0 +/- 4.3, whereas the mean numbers of ACF in the deguelin groups were 24.8 +/- 2.7, 7.2 +/- 1.5 and 4.6 +/- 1.4 at doses of 2.5, 5.0 and 10.0 mg/kg body weight, respectively. In a similar manner, treatment with deguelin significantly (p < 0.001) suppressed the appearance of hex(-) crypts in a dose-dependent manner. In a second study, the ability of deguelin to block the initiation and promotion stages of colon carcinogenesis was investigated. Greatest inhibition was observed when deguelin was administered during the promotional stage (73.3%, p < 0.001). These results demonstrate that deguelin is an efficacious chemopreventive agent against colon carcinogenesis.
authors.affiliation: Department of Surgical Oncology, College of Medicine, University of Illinois, Chicago, IL 60612, USA.
authors.forename: Genoveva
authors.initials: G
authors.lastname: Murillo
authors.forename: Jerome W
authors.initials: JW
authors.lastname: Kosmeder
authors.forename: John M
authors.initials: JM
authors.lastname: Pezzuto
authors.forename: Rajendra G
authors.initials: RG
authors.lastname: Mehta
mesh_terms: D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D001397:Azoxymethane / Q000633:toxicity; D003106:Colon / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D003110:Colonic Neoplasms / Q000517:prevention & control*; D005260:Female; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D051379:Mice; D015394:Molecular Structure; D010894:Piroxicam / Q000494:pharmacology; D011230:Precancerous Conditions / Q000517:prevention & control*; D012402:Rotenone / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology*; D001619:beta-N-Acetylhexosaminidases / Q000032:analysis / Q000172:deficiency
chemical_list: D016588:Anticarcinogenic Agents; D012402:Rotenone; D010894:Piroxicam; D001619:beta-N-Acetylhexosaminidases; C107676:deguelin; D001397:Azoxymethane